 | Up a level |
Journal Article
Eichhorst, B., Arriola, E., Cerri, E., Verdugo, M., Letschert, K., Mourgues, X., Boughan, S., Pena, G., Wittig, B., Selenko-Gebauer, N., Schuh, A. and Ysebaert, L. (2017). Venetoclax for chronic lymphocytic leukemia: baseline characteristics and safety data from pre-approval cohort programs in the EU. Oncol. Res. Treat., 40. S. 140 - 141. BASEL: KARGER. ISSN 2296-5262
Soumerai, J. D., Barrientos, J. C., Hallek, M., Kipps, T. J., Jones, J. A., Xing, G., Yao, N. S., Ysebaert, L., Stilgenbauer, S. and Zelenetz, A. D. (2016). AN EVALUATION OF THE CLL-IPI SCORE AND COMPREHENSIVE PROGNOSTIC FACTOR ANALYSIS IN PATIENTS WITH R/R CLL IN IDELALISIB PHASE 3 RANDOMIZED STUDIES. Haematologica, 101. S. 53 - 55. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Stauder, R., Eichhorst, B., Hamaker, M. E., Kaplanov, K., Morrison, V. A., Osterborg, A., Poddubnaya, I., Woyach, J. A., Shanafelt, T., Smolej, L., Ysebaert, L. and Goede, V. (2017). Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann. Oncol., 28 (2). S. 218 - 228. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Stilgenbauer, S., Schleinitz, T. Aurran, Hallek, M., Lang, F., Offner, F., Rossi, J. -F., Schroyens, W., Van Den Neste, E., Ysebaert, L., Blum, P., Hocke, J., Kress, U. U. and Zenz, T. (2015). PHASE I, FIRST-IN-HUMAN TRIAL OF BI 836826 (AN ANTI-CD37 ANTIBODY) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). Haematologica, 100. S. 225 - 227. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078